Manuel Alexander Haasis1*, Joyce Anne Ceria1, Wantanee Kulpeng2, Yot Teerawattananon2, Marissa Alejandria3 1 National Center for Pharmaceutical Access and Management (NCPAM), Department of Health, Manila, Philippines, 2 Health Intervention and Technology Assessment Program (HITAP), Department of

Beyond vaccine safety, efficacy and procurement lie licensing and delivery — nations must get ready. There are currently more than 40 candidate vaccines for COVID-19 in clinical evaluation, and more than 150 in preclinical development. Creating a safe and effective vaccine is akin to striking bas

Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: Protection at what price in the Thai context? Wantanee Kulpenga, b, , , , Pattara Leelahavaronga, , Waranya Rattanavipaponga, , Vorasith Sornsrivichaib, , Henry C. Baggettc, , Aronrag Meeyaia, d, , , Warunee Punpaniche, ,

Abstract Background The World Health Organization (WHO) has developed the Total System Effectiveness (TSE) framework to assist national policy-makers in prioritizing vaccines. The pilot was launched in Thailand to explore the potential use of TSE in a country with established governance struct

Summary The COVID-19 pandemic is unlikely to end until there is global roll-out of vaccines that protect against severe disease and preferably drive herd immunity. Regulators in numerous countries have authorised or approved COVID-19 vaccines for human use, with more expected to be licensed in 20

The more controversial of two papers describing how the lethal H5N1 bird flu could be made easier to spread was published Thursday, six months after a scientific advisory board suggested that the papers’ most potentially dangerous data be censored.The paper, by scientists at Erasmus Medical Center i

Abstract Real-world effectiveness studies are important for monitoring performance of COVID-19 vaccination programmes and informing COVID-19 prevention and control policies. We aimed to synthesise methodological approaches used in COVID-19 vaccine effectiveness studies, in order to evaluate which

Kittiphong Thiboonboon1 , Benjarin Santatiwongchai1 ,Varit Chantarastapornchit1 , Waranya Rattanavipapong1 , Yot Teerawattananon1 Abstract Background For more than three decades, the number and influence of economic evaluations of healthcare interventions have been increasing and gaining atte

Background Target Product Profiles (TPPs) serve as strategic tools for planning medical innovation development, facilitating communication with regulators, and developing market access strategies. Modelling can assist TPPs development and provide guidance on defining attributes. This scoping re